Takeda Grows Immuno-Oncology Portfolio With $525m Maverick Acquisition
Japanese Pharma Exercises Option Under 2017 Deal
Executive Summary
Maverick’s bispecific antibody program adds to Takeda’s expanding immuno-oncology development business, which also includes cell therapy programs.
You may also be interested in...
Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
BIO 2021 Notebook: Best Practices For Business Development
The recently concluded BIO annual meeting included several sessions focused on the practice of business development. In this extra edition of our BIO 2021 notebook, Scrip collected observations about best practices for partnerships.
Pipeline Packed As Cash Pours Into Cell And Gene Therapy Space
Cell, gene and RNA therapies are starting to transform the healthcare landscape and a report from the American Society of Gene + Cell Therapy and Informa Pharma Intelligence maps the progress the sector made in the first quarter of 2021.